ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 19 Dec 2022
Last Updated on 19 Dec 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended acarbose for inclusion on the MOH List of Subsidised Drugs for treating type 2 diabetes mellitus due to low clinical need and decreasing utilisation in local practice, unfavourable cost-effectiveness, and availability of multiple subsidised alternatives.


Acarbose for treating type 2 diabetes mellitus (19 December 2022)